Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2018
Oral Abstract Session 16: Tickling the Germline
Targeted Selection of an Improbable HIV-1 Antibody Mutation Critical for Broadly Neutralizing Reactivity With a Designed Immunogen
Kevin Wiehe
Duke University, United States
Carbohydrate Mimicry for Eliciting Oligomannose-targeting Neutralizing Antibodies to HIV-1
Ralph Pantophlet
Simon Fraser University, Canada
Vaccine Induction of VRC01-class Neutralizing Antibodies in a Knock-in Mouse Model
Xuejun Chen
Vaccine Research Center/NIAID/NIH, United States
Phenotypic Deficits in the HIV-1 Envelope Are Associated With the Maturation of a V2-directed Broadly Neutralizing Antibody Lineage
Lucia Reh
University of Zurich, Switzerland
Chimpanzee SIV Envelope-derived Trimer Guides an Immunofocused HIV Cross-neutralizing Ab Response in V2-apex bnAb UCA Expressing Knock-in Mice
Raiees Andrabi
The Scripps Research Institute, United States
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 17: Factors Influencing Viral Transmission and Spread
HLA Pre-adaptation in Gag Influences Viral Evolution in the New Host
Daniela Monaco
Emory University, United States
Treatment of Schistosoma mansoni Infection in Ugandan Women Reduces HIV Entry Into Cervical CD4 T Cells and Induces Type I Interferon Pathways
Rupert Kaul
University of Toronto, Canada
The Eclipse Phase Lasted a Week in HIV-1-infected Adults in East Africa and Thailand
Morgane Rolland
MHRP | HJF, United States
Infection With Multiple Transmitted/Founder (TF) HIV-1 Viruses Impacts Peak VL and HIV-1 Pathogenesis
Gladys Macharia
IAVI Human immunology Lab, Imperial College London, United Kingdom
Localization of Infection in Neonatal Rhesus Macaques After Oral Viral Challenge
Roslyn A. Taylor
Northwestern University, United States
Gp41 Ectodomain-specific IgG is Associated with Increased Vertical HIV-1 Transmission
Nicole Naiman
Fred Hutchinson Cancer Research Center, United States
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 18: Opinion 360: Meaningful Engagement From Research to Roll Out
Beneficial Impacts Related to Participating in an International HIV Prevention Trial Involving People Who Inject Drugs
Jeremy Sugarman
John Hopkins, United States
Standardized Metrics Can Reveal Region-specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials
Gail Broder
Fred Hutchinson Cancer Research Center, United States
Ethical Considerations for Involving Adolescents Aged 16-17 in HIV Prevention Clinical Trials: Community Perspectives from Uganda
Rita Nakalega
Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration, Uganda
The Luxuriant Future of Microbicides: Planning for Success
Marc-André LeBlanc
HIV Prevention Advocate, Canada
Planning for PrEP: Facilitating Collaborative Cross-country Learning
Neeraja Bhavaraju
FSG, United States
Princess PrEP Program: A Successful Key Population-led PrEP Model in Thailand Forming Through Meaningful Participation of Key Populations
Nittaya Phanuphak
Thai Red Cross AIDS Research Centre, Thailand
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 19: Stay With Me: Retention on PrEP
PrEP Uptake and Retention Among Men and Women Receiving PrEP Integrated in Public Health HIV Care Clinic Settings
Kenneth Mugwanya
University of Washington, United States
Examining PrEP Interruptions in a Safety-net Primary Care Network: Missed Opportunities to Re-engage PrEP Users Accessing non-PrEP Services
Matthew Spinelli
University of California, San Francisco, United States
Early Persistence of HIV Pre-exposure Prophylaxis (PrEP) in African Adolescent Girls and Young Women (AGYW) from Kenya and South Africa
Elzette Rousseau-Jemwa
Desmond Tutu HIV Foundation, South Africa
Intimate Partner Violence and Early PrEP Adherence Among Adolescent Girls and Young Women in Cape Town, South Africa: A Longitudinal Analysis
Sarah T. Roberts
RTI International, United States
Early Antiretroviral Therapy and Daily Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin: A Demonstration Study
Michel Alary
CHU de Québec, Canada
Trends in Engagement in the HIV Prevention and the Care Cascade among Young Women who Sell Sex in Zimbabwe
Sue Napierala
RTI International, United States
from HIV Research for Prevention 2018 on 25 October 2018 08:30-10:00
Oral Abstract Session 20: Into the Future With Delivery Technologies
Nanoparticles-in-thermosensitive Enemas as Potential Vehicles for Microbicide Development
Mélanie Melo
i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, Portugal
Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)
Ariane van der Straten
RTI International, United States
Tenofovir Douche for PrEP: On-demand, Behaviorally-congruent Douche Rapidly Achieves Colon Tissue Concentration Targets (DREAM 01 Study)
Ethel Weld
Johns Hopkins University, United States
Self-administered Griffithsin and Carrageenan Containing Microbicide Fast-dissolving Insert as Pre-exposure Prophylaxis Against HIV and HPV Infections
Thomas Zydowsky
Population Council, United States
Innovative 3D Printed Intravaginal Rings: Reengineering Multipurpose Intravaginal Rings for Prevention of HIV and Unintended Pregnancy
S. Rahima Benhabbour
University of North Carolina, Chapel Hill, United States
The Dapivirine and Levonorgestrel MPT Ring: Understanding the Levonorgestrel Binding Reaction with Silicone Elastomer
Karl Malcolm
Queen's University Belfast, United Kingdom
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Oral Abstract Session 21: Linking Arms in Defense: Innate, Cellular and Humoral
Vaccine-induced Activation of Inflammasome in Classical Monocytes and Th2 Cell Responses Correlates With Decreased Risk of SIVmac251 Acquisition
Monica Vaccari
NCI, NIH, United States
Soluble Immune Activation Biomarkers Predict Accelerated Viral Rebound During Treatment Interruption in Fiebig I-treated Individuals
Bonnie M. Slike
US Military HIV Research Program/WRAIR, United States
Recombinant MVA Prime Elicits Neutralizing Antibody Responses by Inducing Antigen-specific B Cells in the Germinal Center
Sampa Santra
Beth Israel Deaconess Medical Center, Harvard Medical School, United States
Targeting HIV gp140 Env to Human Langerhans Cells Drives Tfh Differentiation and Antibody Responses
Jérôme Kervevan
Inserm U955 - Institut Mondor de Recherche Biomédicale, UPEC, France
Broadly Neutralizing Antibodies in Children Correlate With Increased HIV-specific T-follicular Helper and Regulatory Cells Within Germinal Centers
Julia Roider
Ludwig-Maximilians-University, Germany
The Impact of Vaccination on SIV Evolution Following Break-through Infection
Kathryn Foulds
VRC/NIAID/NIH, United States
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Oral Abstract Session 22: Antibody Virus Tango
Targeted Viral Selection Is Associated With the Development of HIV Broadly Neutralizing Antibodies
Batsirai Mabvakure
Center for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa
Next-generation Sequencing Delineates the Developmental Pathway of Fusion Peptide-directed Broadly Neutralizing Antibody N123-VRC34.01
Chen-Hsiang Shen
Vaccine Research Center, NIAID, NIH, United States
Early Antibodies Against the Transmitted/Founder HIV-1 Envelope gp120 Are Dominated by the Immunoglobulin Heavy Chain Germline VH1-69
S. Abigail Smith
Emory University, United States
“Designer” SHIVs Elicit V2 bNAbs in Rhesus Macaques
Ryan S. Roark
University of Pennsylvania, United States
eCD4-Ig Is More Difficult to Escape Than Broadly Neutralizing Antibodies
Christoph H. Fellinger
The Scripps Research Institute, United States
Defining and Characterizing the ‘Escapability' of Potent Broadly Neutralizing Antibodies Against HIV in Humanized Mice
Cailin Deal
The Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Oral Abstract Session 23: Great Expectations: The Impact of PrEP
HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure Prophylaxis (PrEP): Worldwide Experience From 46 Studies
Jared Baeten
University of Washington, United States
Sensitive Next-generation Sequencing of HIV-1 From Seroconverters in the MTN-020/ASPIRE Dapivirine Vaginal Ring Study
Urvi Parikh
University of Pittsburgh, United States
Transgender Women on Estrogen Have Significantly Lower Tenofovir/Emtricitabine Concentrations During Directly Observed Dosing When Compared to Cis Men
Craig Hendrix
Johns Hopkins University, United States
Decreased HIV Incidence Among PrEP Users Compared to Non-users in a Boston Community Health Center, 2012-2017
Kenneth H. Mayer
Fenway Health, United States
Mathematical Modeling to Evaluate the Impact and Cost-effectiveness of Oral Pre-exposure Prophylaxis for HIV Prevention in Uganda
Katharine Kripke
Avenir Health, Project SOAR, United States
Potential Impact of Increased ART and PrEP Coverage on the HIV Epidemic Among MSM in Atlanta: Mathematical Modelling for HPTN 078
Kate M. Mitchell
Imperial College London, United Kingdom
from HIV Research for Prevention 2018 on 25 October 2018 10:30-12:00
Round Table 02: Getting to U: Undetectable = Untransmittable
Starting and Staying on ARVs
Robert H. Remien
NY State Psychiatric Institute and Columbia University, United States
What Are the Population Level Studies Teaching Us about U=U?
Nelly Mugo
Kenya Medical Research Institute (KEMRI), Kenya
What Does U=U Mean for Breastfeeding?
Lena Serghides
University Health Network and University of Toronto, Canada
How Do You Know You're “U”?
John Brooks
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States
U=U: Unpacking the Message and the Movement
Bruce Richman
U=U, United States
Questions
Robert H. Remien
NY State Psychiatric Institute and Columbia University, United States
Nelly Mugo
Kenya Medical Research Institute (KEMRI), Kenya
Lena Serghides
University Health Network and University of Toronto, Canada
John Brooks
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States
Bruce Richman
U=U, United States
from HIV Research for Prevention 2018 on 25 October 2018 13:00-14:30
Symposium 08: Translating Vaccine Concepts to the Clinic: What We Need to Know
Insights Into NK Cell Suppressor Activity in Secondary Lymphoid Organs Revealed by Animal Models
Michaela Muller-Trutwin
Institut Pasteur, France
Influence of Vaccine Composition on Envelope Recognition by HIV-1 Vaccine-induced Antibody-dependent Cellular-mediated Cytotoxic Responses
Guido Ferrari
Duke University Medical Center, United States
Antibody Interference and Durable Monocyte Innate Memory Decrease SIVmac251 Acquisition Risk Following Immunization with the DNA/ALVAC/gp120 Regimen
Genoveffa Franchini
National Cancer Institute, United States
Protective Gene Expression Signature of the RhCMV/SIV Vaccine: Lessons for Human Studies
Michael Gale
University of Washington, United States
Modulating Durability of HIV-1 Env Specific Humoral Immunity With 3M-052, a TLR7/8 Targeted Adjuvant
Sudhir Kasturi
Emory University, United States
from HIV Research for Prevention 2018 on 25 October 2018 13:00-14:30
Symposium 09: Choosing to Use: What People Want from HIV Prevention
Defining and Supporting Prevention Adherence
Jessica Haberer
Massachusetts General Hospital/Harvard Medical School, United States
Risk Perception and End-users' Perspective: Insights From Research of MPTs and HIV Prevention Products
Ariane van der Straten
RTI International, United States
Creating Demand for HIV Prevention Products, Programs and Services
Wanjiru Mukoma
LVCT Health, Kenya
Preference and Habits: How Do Users Decide and How Do We Find Out?
Ram Prasad
Final Mile, United States
from HIV Research for Prevention 2018 on 25 October 2018 13:00-14:30
Symposium 10: Mucosal Environment: Barriers and Facilitators of Transmission
Microbiota and HIV Transmission
Heather Jaspan
University of Cape Town/ Seattle Children's Research Institute, South Africa
High Prevalence of Bacterial STIs in HIV-positive Persons: Transmission Implications & Potential Interventions
Connie Celum
University of Washington, United States
The Rectal Mucosa in At-risk Men who Have Sex With Men: HIV Target Cells and the Inflammatory Response to Condomless Receptive Anal Intercourse
Colleen Kelley
Emory University School of Medicine, United States
How Do Different Components of the Mucosal Microenvironment Interact to Influence HIV Susceptibility?
Cara Wilson
University of Colorado, United States
from HIV Research for Prevention 2018 on 25 October 2018 13:00-14:30
Closing Plenary: Putting It Together: Strategies to End the Epidemic
Young Women’s Leadership Initiative
Multi-disease Approaches to Combination Prevention - Insights from Rural East Africa
Diane Havlir
University of California at San Francisco, United States
Implementing a Multi-disciplinary Prevention Revolution
Maureen Luba
Centre for the Development of People (CEDEP), Malawi
The Impact of Prevention Strategies on HIV Incidence in a Community Center
Michael Meulbroek
BCN Checkpoint, Spain
A Path Forward for HIV Vaccines
John Mascola
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States
Panel Discussion with Closing Plenary Speakers
Diane Havlir
University of California at San Francisco, United States
Maureen Luba
Centre for the Development of People (CEDEP), Malawi
Michael Meulbroek
BCN Checkpoint, Spain
John Mascola
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States
Closing Remarks and Handover to 2020
Susan Buchbinder
San Francisco Department of Public Health, United States
from HIV Research for Prevention 2018 on 25 October 2018 15:00-16:30
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2018